Radioactive beads could make liver tumors operable for colorectal cancer patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed primary adenocarcinoma of the colon or rectum * Potentially resectable colorectal liver metastases, with limiting factors for resection including: 1. Insufficient future liver remnant. 2. Unfavorable tumor location (e.g. involvement of a major vessel and/or bile duct)/ large size and/ or number of lesions, which limit resection with R0 margins and requires downsizing of the metastases * No or limited extrahepatic metastatic disease (limited extrahepatic disease should be amenable to eradicate with locoregional therapies as per multidisciplinary discussion of surgeons, radiation oncologists and interventional radiologists) * Patient should match standard 90Y radioembolization inclusion criteria: 1. Signed informed consent; 2. Age ≥ 18 years; 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 4. Life expectancy of ≥ 3 months; 5. Measurable target tumors in the liver according to RECIST 1.1 * Laboratory parameters: eGFR \>45/mL/min/1.73 m2; albumin \> 3.0 g/dl, normal bilirubin (unless Gilbert syndrome); aminotransferase (ALAT/ASAT) \<3.0 ULN Exclusion Criteria: * Life expectancy ≤3 months * Patient initially eligible for surgery or thermal ablation of the liver metastases * Progressive extra-hepatic disease * Active extra-hepatic disease that cannot be treated * Life-threatening extra-hepatic disease (i.e. dialysis, unresolved diarrhea, serious unresolved infections (HIV, HBV, HCV etc.)) * Uncorrectable coagulopathy * Contraindication for angiography or MRI * Significant toxicities due to prior cancer therapy that have not resolved before the initiation of the study; if the investigator determines that the continuing complication will compromise the safe treatment of the patient * Any surgical contraindication * Ascites * Expected difficulties for safe execution of TARE based on pretreatment Tc99m-MAA imaging, including; * Flow to extra-hepatic vessels not correctable by reposition of catheter or embolization Uncorrectable estimated dose to the lungs \>30Gy in a single administration or \>50Gy cumulatively * Uncorrectable estimated dose to the untreated liver of \>70Gy * Estimated average dose to the viable tumor volume \<200Gy * Prior liver radiotherapy * Severe portal hypertension * Second primary malignancy within the past 5 years, other that adequately treated non-melanoma skin cancer, carcinoma in situ of any organ or second primary colorectal cancer * Unresectable primary tumor in situ; * Other serious comorbidity or any other condition, that renders patients unsuitable for the study treatment * Pregnancy, lactation or refusal to use adequate contraceptive measures * History of allergic reaction to any components of the treatment that cannot be medically corrected.